Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSCF AB Science	$1.26	$1.42	$0.80 ▼ $1.60	N/A	N/A	200 shs	N/A
CHGCY Chugai Pharmaceutical	$23.26 0.0%	$25.83	$18.39 ▼ $31.26	$76.55B	0.66	201,992 shs	686,729 shs
ETNB 89BIO	$11.12 +1.1%	$9.56	$4.16 ▼ $11.84	$1.62B	1.28	1.53 million shs	1.31 million shs
TGIF SoFi Weekly Income ETF	$97.49 0.0%	$97.49	$92.22 ▼ $99.07	$16.57M	0.29	2,300 shs	3,300 shs
ULGX Urologix		$0.00	$0.00 ▼ $0.04	N/A	-39.24	N/A	N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSCF AB Science	0.00%	0.00%	0.00%	-19.75%	-53.33%
CHGCY Chugai Pharmaceutical	0.00%	-4.87%	-10.19%	+1.04%	+16.70%
ETNB 89BIO	0.00%	+8.48%	+5.67%	+85.81%	+25.28%
TGIF SoFi Weekly Income ETF	0.00%	0.00%	0.00%	0.00%	0.00%
ULGX Urologix	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABSCF AB Science	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CHGCY Chugai Pharmaceutical	1.0211 of 5 stars	0.0	3.0	2.5	0.0	2.0	0.0	0.6
ETNB 89BIO	2.1121 of 5 stars	3.5	1.0	0.0	0.0	3.3	0.8	0.6
TGIF SoFi Weekly Income ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSCF AB Science	0.00	N/A	N/A	N/A
CHGCY Chugai Pharmaceutical	0.00	N/A	N/A	N/A
ETNB 89BIO	3.00	Buy	$26.43	137.67% Upside
TGIF SoFi Weekly Income ETF	0.00	N/A	N/A	N/A
ULGX Urologix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CHGCY, TGIF, ULGX, ETNB, and ABSCF Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/12/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/10/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/30/2025	ETNB 89BIO	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSCF AB Science	N/A	N/A	N/A	N/A	N/A	N/A
CHGCY Chugai Pharmaceutical	$7.74B	9.89	$0.84 per share	27.64	$3.81 per share	6.10
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
TGIF SoFi Weekly Income ETF	N/A	N/A	N/A	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSCF AB Science	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/30/2025 (Estimated)
CHGCY Chugai Pharmaceutical	$2.56B	$0.81	28.72	29.82	N/A	33.56%	21.71%	18.98%	7/24/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.38	N/A	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
TGIF SoFi Weekly Income ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest CHGCY, TGIF, ULGX, ETNB, and ABSCF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	ETNB 89BIO	-$0.49	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	ETNB 89BIO	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A
4/24/2025	Q1 2025	CHGCY Chugai Pharmaceutical	N/A	$0.19	N/A	$0.19	N/A	$1.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSCF AB Science	N/A	N/A	N/A	N/A	N/A
CHGCY Chugai Pharmaceutical	$0.26	1.12%	N/A	32.10%	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
TGIF SoFi Weekly Income ETF	$4.03	4.13%	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSCF AB Science	N/A	N/A	N/A
CHGCY Chugai Pharmaceutical	N/A	7.28	6.16
ETNB 89BIO	0.06	18.03	18.03
TGIF SoFi Weekly Income ETF	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSCF AB Science	N/A
CHGCY Chugai Pharmaceutical	0.01%
ETNB 89BIO	N/A
TGIF SoFi Weekly Income ETF	N/A
ULGX Urologix	N/A

Insider Ownership

Company	Insider Ownership
ABSCF AB Science	N/A
CHGCY Chugai Pharmaceutical	N/A
ETNB 89BIO	2.80%
TGIF SoFi Weekly Income ETF	N/A
ULGX Urologix	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSCF AB Science	51	N/A	N/A	Not Optionable
CHGCY Chugai Pharmaceutical	7,778	3.29 billion	N/A	Not Optionable
ETNB 89BIO	40	145.98 million	141.90 million	Optionable
TGIF SoFi Weekly Income ETF	N/A	170,000	N/A	Not Optionable
ULGX Urologix	61	N/A	N/A	Not Optionable

CHGCY, TGIF, ULGX, ETNB, and ABSCF Headlines

Recent News About These Companies

Urologix, Inc. (ULGX)

October 3, 2024 | finance.yahoo.com

21st North (ULGX) Earnings Dates & Reports

August 23, 2024 | investing.com

Latest Market Study | Anti-Snoring Devices Market Size, Share, Trends, Industry Analysis & Forecasts, 2023-2030

November 15, 2023 | finance.yahoo.com

Suoxinda Holdings Ltd (3680)

July 29, 2023 | investing.com

Create Capital Vietnam Limited JSC (CRC)

July 13, 2023 | investing.com

Benign Prostate Hyperplasia (BPH) Treatment Market Report 2023: Product Launches Continue to Boost Market

May 1, 2023 | finance.yahoo.com

Urologix, Inc. (ULGX) Stock Historical Prices & Data - Yahoo Finance

March 7, 2023 | finance.yahoo.com

Urologix Year to Date Total Returns (Daily)

December 18, 2021 | ycharts.comY

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHGCY, TGIF, ULGX, ETNB, and ABSCF Company Descriptions

AB Science OTCMKTS:ABSCF

$1.26 0.00 (0.00%)

As of 07/11/2025

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Chugai Pharmaceutical OTCMKTS:CHGCY

$23.26 -0.01 (-0.04%)

As of 03:59 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

89BIO NASDAQ:ETNB

$11.12 +0.12 (+1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$11.12 0.00 (-0.04%)

As of 07:22 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

SoFi Weekly Income ETF NYSEARCA:TGIF

$97.49 -0.04 (-0.04%)

As of 02/20/2024

The SoFi Weekly Income ETF (TGIF) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is the first actively managed USD-denominated fixed income ETF aiming to provide weekly distributions to investors. TGIF was launched on Oct 1, 2020 and is managed by SoFi.

Urologix OTCMKTS:ULGX

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time